Skip to main content
Juan Lertora, MD, Internal Medicine, Baton Rouge, LA

JuanJose LuisLertoraMD

Internal Medicine • Baton Rouge, LA

Physician

Join to view full profile

Dr. Lertora is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lertora's full profile

Already have an account?

Education & Training

  • University of Connecticut
    University of ConnecticutResidency, Internal Medicine, 1975 - 1977
  • Other
    OtherClass of 1970

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1977 - 2026
  • LA State Medical License
    LA State Medical License 1980 - 2024
  • CT State Medical License
    CT State Medical License 1977 - 2022
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • Clinical Evaluation Of Flowable Composite ResinNational Center For Research Resources2006
  • Trial Of Two Potent, Simplified Regimens Utilizing A Protease Inhibitor-SparingNational Center For Research Resources2005
  • Quality Assessment Study For Viable Peripheral Blood Mononuclear Cells (PBMC)National Center For Research Resources2005
  • Trial Of Two Potent, Simplified RegimensNational Center For Research Resources2004
  • Study Of Prolongation Of Virologic Success And Options From Failure In HIVNational Center For Research Resources2004
  • Quality Assessment Study For PbmcsNational Center For Research Resources2004
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–2002
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–2002
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–2002
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–2002
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–2002
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–2002
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–2002
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–2002
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–2002
  • AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1996–2002
  • Salvage Antiretroviral TherapiesNational Center For Research Resources2000–2001
  • Protein Supplements In HIV+ Subjects With Weight LossNational Center For Research Resources2000–2001
  • Protease Inhibitors And Lipid Lowering AgentsNational Center For Research Resources2000–2001
  • Protease Inhibitor/Non-Nucleoside RT InhibitorNational Center For Research Resources2000–2001
  • Phase II Study Of Hydroxyurea In HIV InfectionNational Center For Research Resources2000–2001
  • Oncogenic Viral Pathogenesis/Cancer Risk Factors In AIDSNational Center For Research Resources2000–2001
  • Interleukin 2 PLUS Highly Active Antiretroviral TherapyNational Center For Research Resources2000–2001
  • ACTG 398:Amprenavir As PART Of Dual Protease Inhibitor Regimens In HINational Center For Research Resources1999–2001
  • ACTG 388:Trial Of Efavirenz Or Nelfinavir In Combination W/ 3tc/Zdv &National Center For Research Resources1999–2001
  • ACTG 372:Study Of Prolongation Of Virologic Success &Options From FANational Center For Research Resources1999–2001
  • ACTG 368--Trial Of 1592U89 In Combination W/ IDV And Dmp-266 In HIV+National Center For Research Resources1998–2001
  • ACTG 343--Trial Of 3 Maintenance Regimens For HIV+ SubjectsNational Center For Research Resources1998–2001
  • ACTG 328--Intermittent Recombinant Human IL2 + Haart VS Haart Alone--AidsNational Center For Research Resources1998–2001
  • ACTG 383:Dynamics Of Hepatitis C In Patients Infected W/ Hepatitis CNational Center For Research Resources1999–2000
  • ACTG 309:Pharmacokinetics Of Antituberculosis Agents In HIV InfectedNational Center For Research Resources1999–2000
  • ACTG 359--Activity Of Soft Gelatin Capsule Saquinavir In Combination--Hiv+National Center For Research Resources1998–2000
  • ACTG 313--Megestrol Acetate/Testosterone Enanthate Combination VS Alone In AIDSNational Center For Research Resources1998–2000
  • ACTG 320--Phase III Study Of Indinavir With ZDV And 3TC In Subjects With HIVNational Center For Research Resources1997–2000
  • ACTG 248--Phase II Study Of IL 2 By Subcutaneous Injection Of Hiv/AntiretroviralNational Center For Research Resources1997–2000
  • ACTG 336--Study Of Nitazoxanide (NTZ) For AIDS CryptosporidiosisNational Center For Research Resources1998–1999
  • Acetylation Activity In HIV Positive Individuals And The Potential Drug ReactionNational Center For Research Resources1998–1999
  • ACTG 333--Hard Capsule Saquinavir VS Soft Gelatin Saquinavir VS IndinavirNational Center For Research Resources1997–1999
  • Menstrual Cycle And Drug Metabolism--P450 IsozymesNational Center For Research Resources1997
  • Acetylation Activity In HIV Positive Individuals And Potential Drug ReactionNational Center For Research Resources1997
  • Correlation Of Ethylene Dichloride Oxidate Metabolism And ChlorzoxazoneNational Center For Research Resources1996–1997

Dr. Juan Lertora, Dr. Juan Lertora, MD, Dr. J Lertora, Dr. Juan Jose Luis Lertora